Skip to main content
Navigate Up
Sign In
 

Study: No escape from LOXO-101 for TRK-fusion lung cancer


A University of Colorado Cancer Center study presented at the American Association for Cancer Research Annual Meeting 2016 pinpoints ways that cancer cells evolve to resist the drug LOXO-101, a kinase inhibitor of the TRK-fusion genes that drive a subset of cancers. The drug is currently being evaluated in promising phase 1 and phase 2 clinical trials.
 
“We’re showing outstanding results with kinase inhibitors including LOXO-101 to target specific activating genetic abnormalities. However, cancers often evolve in response to these drugs, acquiring or utilizing additional genetic changes that confer resistance. This study shows mechanisms that cancers caused by fusion of the TRK gene use to evade targeted therapies. We hope that by designing drugs to target these mechanisms of resistance, we can augment and prolong the duration of response experienced by patients using LOXO-101 and other medicines in the family of tyrosine kinase inhibitors,” says Robert C. Doebele, M.D., Ph.D., LOXO-101 clinical investigator and CU Cancer Center member.
 
Read more